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Abstract 
Background  
Polycystic liver disease (PLD) is a rare genetic disorder with progressive cyst growth as the 
primary phenotype. Therapy consists of volume reduction through invasive surgical or 
radiological procedures. In order to understand the process of treatment decision, our aim 
was to identify factors that increased the likelihood of treatment. 
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Study Design 
We performed a cross-sectional study using an international population of PLD patients. We 
collected data on the following therapies: liver transplantation, resection, fenestration and 
aspiration sclerotherapy. Data on the potential determinants: sex, center, autosomal 
dominant polycystic kidney disease (ADPKD), autosomal dominant polycystic liver disease 
(ADPLD), age at diagnosis, symptoms and phenotype were included. We corrected for 
follow-up  time.  
Results 
We included 578 patients in our study and 35% underwent invasive therapy. Multivariate 
regression analysis showed that number of symptoms) and age at diagnosis of PLD 
increased the likelihood of treatment (respectively RR 1.4, p<0.001 and RR =1.4, p=0.03). 
The choice for liver transplantation or aspiration sclerotherapy was center-dependent (RR 
0.7, p<0.001 and RR 1.1, p=0.03 respectively).  
Conclusion 
The results of our international cross-sectional study suggests that a higher number of 
symptoms and every 10 years of PLD diagnosis increases the risk to undergo treatment by 
40%. The choice to elect a particular modality is center dependent. 
 
Keywords: autosomal dominant polycystic kidney disease, autosomal dominant polycystic 
liver disease, polycystic liver disease, surgery, treatment 
 
Abbreviations 
ADPKD  Autosomal dominant polycystic kidney disease  
ADPLD  Autosomal dominant polycytic liver disease 
hTLV   Height-adjusted total liver volume 
PLD   Polycystic liver disease 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
RR   Risk ratio 
TLV   Total liver volume 
 
Introduction 
Polycystic liver disease (PLD) is a condition characterized by progressive liver cyst growth. 
(1) PLD is part of the phenotype of two genetically distinct disorders. It is present as a 
primary phenotype in autosomal dominant polycystic liver disease (ADPLD), and it is the 
most common extra-renal manifestation in autosomal dominant polycystic kidney disease 
(ADPKD). (2-4) Isolated PLD is rare with a prevalence of 1 in 158.000, which contrasts that 
of ADPKD which has a higher prevalence (1: 400-1000 individuals). (5, 6) The vast majority 
of ADPKD patients (94%) > 35 years-of-age possess hepatic cysts. (4)  
Although PLD is often asymptomatic, patients who progress to severe hepatomegaly have a 
decreased health-related quality of life and are often in need of therapy. (7, 8) Risk factors 
for progressive disease are age, female sex, estrogen use and pregnancies. (8-11) The 
concept central to PLD therapy is downsizing liver volume as this leads to improvement of 
symptoms. (3) Currently, the mainstay of therapies include invasive surgical and radiological 
procedures such as, liver transplantation, the only curative treatment, resection, fenestration 
and aspiration sclerotherapy.(2, 12) Treatment is indicated in patients who suffer from 
symptomatic hepatomegaly and the choice for a specific therapy mainly depends on the 
presence and location of dominant cysts. (2, 3, 13) Clear guidelines about timing and choice 
of therapy are lacking. This might be explained by a lack of evidence generated by clinical 
trials comparing efficacy of invasive treatment strategies for PLD. In addition, there are no 
standardized outcome measures to assess treatment success in clinical practice, which 
hampers the building of an evidence base.  
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In order to guide physicians on therapy, it is necessary to explore factors involved in the 
process of treatment decision. To this end, we aimed to delineate patient characteristics and 
disease-specific factors that trigger therapy. Our secondary aim was to identify determinants 
that increased the likelihood of a specific invasive therapy for PLD.  
 
Materials and methods 
Study design and subjects 
We performed a cross-sectional study that included PLD patients coming from two 
independent PLD registries. Both registries were developed at two nationwide referral 
hospitals for PLD, Radboud university medical center Nijmegen in the Netherlands (center 1) 
and University Hospital of Leuven in Belgium (center 2).(14) Both hospitals are national 
referral centers for clinical evaluation and treatment of PLD. The Dutch registry contains all 
PLD patients who have visited the outpatient clinic of the Department of Hepatology of the 
Radboud university medical center between January 2008 and February 2015. Patients with 
ADPKD who had visited the Department of Nephrology between January 2008 and 
December 2014 were included, if PLD was present. The Belgium registry includes all PLD 
patients who had visited the outpatient clinic of the Department of Hepatology of the 
University Hospital of Leuven, from January 2008 to July 2015. According to the Dutch and 
Belgium regulations, these registries do not need formal ethical approval as this was an 
observational study. 
The inclusion criterium for this analysis was a diagnosis of PLD as documented by patients’ 
physician where diagnosis of PLD had literally to be written down in the medical file of 
patients, or as shown on radiological imaging by the presence of ≥20 hepatic cyst larger than 
0.5 cm. Underlying diagnosis of ADPKD or ADPLD was a requirement. ADPKD diagnosis 
was based upon modified Ravine criteria (15) and ADPLD diagnosis was based on the 
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presence of ≥ 20 liver cysts, in the absence of renal cysts. If renal cysts were present in 
patients with ADPLD, the Ravine criteria should not be met. (16) Patients with hepatic cysts 
due to other diseases (e.g. Caroli’s disease, autosomal resistant polycystic kidney disease) 
were excluded.  
 
Potential determinants for treatment 
We selected the following patient characteristics and disease-specific factors as potential 
determinants for treatment: sex, age at PLD diagnosis, phenotype, underlying diagnosis of 
PLD (ADPKD or ADPLD), number of symptoms, total liver volume (TLV), height adjusted 
TLV (hTLV), estrogen use and history of pregnancy. Center was also added as a factor 
determining choice of treatment. Parameters that pertained treatment decision were chosen 
on basis of expert opinion, and evidence coming from studies on risk factors for severe PLD. 
(5, 9-11)   
 
Data collection 
Data were retrospectively collected from medical  charts of patients. We included information 
on the following invasive treatment modalities: liver transplantation (combined with or without 
renal transplantation), resection, fenestration and aspiration sclerotherapy. Experimental 
therapies such as somatostatin analogues were excluded since these drugs are mainly used 
in clinical trial settings. We reviewed medical charts for demographics, underlying diagnosis 
of PLD, age at diagnosis of PLD, TLV, hTLV, estrogen use and pregnancies. We used the 
most recent value for TLV that was available. Liver volumes had been calculated in the past 
by 3D measurements of CT scans. This included manually outlining of the liver every 9 mm 
with interpolation of intermediate slices and calculation of TLV. We also collected data on 
hepatic cyst phenotype by assessing MRI, CT, ultrasound images or reviewing imaging 
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reports. We have distinguished between a phenotype with either the presence or absence of 
one or more dominant cysts (≥ 8cm). Finally, we collected data on the presence of the 
following symptoms in medical records of patients: abdominal discomfort, feeling full, 
abdominal pain, tiredness, pain in the rib cage and pain in the side. These symptoms were 
selected as they were overrepresented in a Dutch population of symptomatic PLD patients. 
(17)  
 
Statistical analysis 
We performed descriptive statistical analyses to summarize population characteristics. 
Baseline continuous variables were expressed in mean (standard deviation (SD)) for 
normally distributed data or median (interquartile range (IQR)) for non-normally distributed 
data. Dichotomous outcomes were expressed as % (n/n total). 
For our primary and secondary aim, we used multivariate logarithmic linked modified 
Poisson regression analysis to generate risk ratios (RR) for determinants associated with 
respectively treatment and specific treatment modalities. (18, 19) Risk ratios >1 and <1 were 
interpreted as respectively increasing and decreasing the likelihood of treatment or a specific 
therapy, while a risk ratio equal to 1 with a 95% CI smaller than 1 indicates no association 
We included a potential determinant in the regression model only if at least 10 patients 
(1.7% of 578 patients) were exposed to the determinant to guarantee adequate statistical 
power.  For the primary analysis, the dependent variable was specified as treatment or no 
treatment, whereas treatment was defined as patients who underwent surgical or 
radiological therapy, at least once. Independent variables included sex, center, age at 
diagnosis of PLD (defined as age at diagnosis of PLD divided by 10 years), phenotype, 
underlying diagnosis (ADPKD or ADPLD), number of symptoms, TLV, hTLV, estrogen use 
and pregnancy in history. We added the variable follow-up, defined as  interval from 
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diagnosis to inclusion in the study divided by 10 years to the model in order to correct for 
follow-up  period. 
For our secondary analysis, liver transplantation, resection, fenestration and aspiration 
sclerotherapy were included as dependent variables. In this analysis, the same independent 
variables as for the primary analysis were included. Unpaired student’s t-test or Chi-square 
test were used to compare patient- or disease characteristics between specific treatment 
modalities. In addition, a sub-group analysis of hepatic phenotype and treatment strategy 
between ADPKD and ADPLD patients was performed. Finally, we tested whether patients 
who underwent aspiration sclerotherapy or fenestration differed on sex, center, age at 
diagnosis of PLD, phenotype and underlying diagnosis of PLD. If patients underwent 
aspiration sclerotherapy and fenestration, the first treatment that was given was used for this 
analysis. A p-value of <0.05 was considered statistical significant. Data were analyzed using 
SPSS 22.0 (SPSS Statistics, Inc., Chicago, IL, U.S.A.). 
 
Results 
Characterization of the study population 
We included 578 patients in our study population and 200 (35%) underwent invasive therapy 
(Figure 1). The large majority of patients were female (81%) and 383 (66%) had an 
underlying diagnosis of ADPKD (Table 1). A total of 421 patients showed a phenotype 
without dominant cysts while a phenotype with concomitant dominant cysts was present in 
54 patients. Liver phenotype significantly differed between ADPKD and ADPLD patients 
(Figure 2). ADPLD patients possessed dominant cysts on radiological imaging in 34 patients 
(22%) whereas this was the case in only 21 of ADPKD patients (7%) (p <0.001).  
Most patients were Dutch (66%, n=380) and stratification of patients by center demonstrated 
that populations from both centers were comparable with respect to sex, TLV and hTLV 
(Table S1). Dutch patients had more symptoms, were more often diagnosed with ADPLD, 
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diagnosed at a later age, and more often possessed a phenotype without dominant cysts. 
The follow-up of patients at the university hospital of Leuven in Belgium was significantly 
longer than the follow-up of patients at the Radboudumc in the Netherlands (18 vs. 7 years, 
p <0.001). Therefore all analysis were corrected for follow-up time by including this in the 
multivariate model. 
 
Determinants that trigger treatment  
Liver transplantation, resection, fenestration and aspiration sclerotherapy were performed in 
respectively 13%, 1%, 8% and 17% of patients (Figure 1). Multivariate regression analysis 
revealed that patients who suffer from more symptoms have a 40% higher likelihood (CI: 
1.17-1.60, p<0.001) to receive treatment (Figure 3). Every 10 years of diagnosis of PLD was 
also significantly associated with a 40% increased risk of treatment (CI: 1.04-1.88, p=0.03) ). 
. TLV, hTLV, estrogen use and pregnancy in history were not included in the regression 
analyses as data were missing in respectively 56%, 72%, 54% (women only) and 49% 
(women only) of patients.  
 
Characterisation of patient undergoing invasive therapy  
Table S3. provides an overview of patient and disease characteristics of individuals who 
underwent respectively transplantation, resection, fenestration and aspiration sclerotherapy. 
Liver transplantation was done at a median age of 53 ±10years in a total of 77 patients of 
whom 69 were diagnosed with ADPKD. In 43% (n=33) of patients this was combined with a 
renal transplantation and radiological imaging showed a median TLV of 4271 mL [IQR 3438-
6243 mL] in these patients. Resection was done in 6 patients (1%) and most patients 
underwent other treatment modalities as well. Interestingly, a total of 27 patients received >1 
different treatment modality. A combination of fenestration and aspiration sclerotherapy was 
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most common (9%, n=17). Only a small proportion of the total study population underwent 
fenestration (8%, n=48) and a minority of them had ADPKD (38%, n=18). Patients who 
underwent fenestration or aspiration sclerotherapy did not significantly differ on sex, 
diagnosis, age at diagnosis and phenotype (Table S4). We found that the choice for 
fenestration or aspiration sclerotherapy was mainly center dependent (p<0.001). Aspiration 
sclerotherapy was most frequently performed with a total of 197 procedures in 100 patients. 
Half of patients (49%, n=97) had > 1 procedure (range 1-15 procedures) and the majority of 
patients were diagnosed with ADPLD (65%, n=65).  
 
Determinants associated with invasive therapies 
We tested the association of six potential determinants with the likelihood to undergo either 
liver transplantation, fenestration or aspiration sclerotherapy (Figure 3, Table S5). 
Determinants associated with hepatic resection were not analyzed as only 7 patients (1%) 
underwent this procedure and a minimum of 10 patients was required. Patients from center 2 
had a 30% higher likelihood (p<0.001) to receive a liver transplantation compared to patients 
from center 1 (Table S5). .The likelihood to undergo a liver transplantation increased by 4% 
with every 10 years of PLD diagnosis (RR 1.035, CI: 1.005-1.065). Multivariate analysis 
revealed that a diagnosis of ADPLD increased the likelihood to undergo fenestration by 30% 
(p<0.05). The number of symptoms was associated with a higher likelihood to undergo 
aspiration sclerotherapy (RR 1.1, p<0.001) . The likelihood to be subjected to aspiration 
sclerotherapy was center dependent (RR 1.1, p=0.03) and increased by follow-up time 
(RR=1.1, P=0.002). 
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Therapy differs between ADPKD and ADPLD patients 
We subsequently explored whether treatment strategies differed between ADPKD and 
ADPLD patients. Fenestration and aspiration sclerotherapy were significantly more often 
performed in ADPLD than in ADPKD patients (15% vs. 5% and 33% vs. 9%, both p<0.001) 
(Figure 4). By contrast, ADPKD patients more frequently underwent liver transplantation 
(18% vs. 4%, p<0.001). In a total of 33 patients undergoing liver transplantation, this was 
combined with a renal transplantation on the same day.  
 
Discussion 
The results of our large cross-sectional study demonstrate that number of symptoms and 
age at diagnosis of PLD increased the likelihood to receive treatment for PLD. The choice for 
either liver transplantation or aspiration sclerotherapy was center-dependent. This 
underscores a certain arbitrariness, probably due to a lack of evidence that supports any of 
the available treatment options. 
A previous review suggests that the natural course of PLD in ADPLD and ADPKD is similar. 
(3) Our study suggests otherwise, and demonstrates that ADPLD patients more often 
possessed large dominant cysts, a phenotype that is amendable to treatment with 
fenestration or aspiration sclerotherapy. (3) The available therapies for patients without 
dominant cysts, most often ADPKD patients, are resection or liver transplantation.(2, 3) A 
resection is a high risk procedure and not often performed in our population. Liver 
transplantation is a very invasive procedure, in particular for a disease that does not lead to 
liver failure or death. In view of a lack of donors, it is not offered widely. (2, 3) These reasons 
probably explain why only 13% of this severe PLD population was transplanted while a 
higher percentage is in need of curative therapy. Interestingly, 90% of the transplanted 
patients were female. This might be explained by a more severe disease course in women, 
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probably due to the effect of estrogen. (9)  However, diagnosis was not significantly 
associated with any of the invasive therapies. These results are in contradiction with a cohort 
study showing that aspiration sclerotherapy was significantly more performed in ADPLD 
patients, while ADPKD patients were more often considered for liver transplantation. (20)  
About 14% of our treated study population underwent subsequent treatments. The 
combination of fenestration and aspiration sclerotherapy was the most frequently chosen 
option. In view of the comparable patients‘ characteristics, our data lend support to center 
specific decision making when it comes to the choice between both treatment modalities. 
These findings indicate that available expertise drives treatment while evidence that singles 
out the best treatment modality is lacking. A randomized controlled trial comparing 
effectiveness of fenestration and aspiration sclerotherapy is necessary to find out which 
treatment strategy is most effective. At the minimum, we should assess treatment outcomes 
in clinical care of PLD in an uniform fashion. Assessment of TLV, symptoms and health-
related quality of life before and after treatment should become standard of care and 
collected in a registry to build an evidence base of treatment efficacy.(14) In addition, our 
results demonstrated that liver transplantation was more frequently performed in Belgium 
while in the Netherlands there was a preference for aspiration sclerotherapy. Due to a 
different organ donor policy, Belgium has more donors available. This might lower the 
threshold for physicians to offer transplantation as a treatment option.  
Our study also discovered that a large proportion of patients received treatment (35%), 
which is at odds with literature that indicates that only a small subset of patients is 
symptomatic. (2, 3, 12) Our population consists of patients referred to two nationwide tertiary 
referral centers, which may have contributed to a selection of a population with more severe 
disease. This may overestimate the disease burden of PLD in this population as referral to 
these centers is often triggered by presence of symptoms. The threshold to treat PLD 
patients is probably lower in tertiary centers because of wider experience with PLD and its 
treatment options.  
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The strength of our study was the large, international study population (n=578) in view of the 
rarity of PLD. In addition, both ADPKD and ADPLD patients were represented in this study 
as well as the most prevalent surgical therapies. Patients from all over the country are 
referred to one of both centers and therefore this study provides a good overview of the 
clinical profile of treated patients in both countries and made it possible to study the effect of 
center on treatment decision. 
The main limitation of our study is the cross-sectional design. We were able to investigate 
factors involved in treatment decision, but it is impossible to infer causality. The retrospective 
data collection has led to missing data and therefore liver volume could not be included as 
potential determinant in our prediction model. Assessment of liver volume is time consuming 
and trained staff and software is required. This might explain the amount of missing data for 
TLV. Although, it is questionable whether liver volume plays a major role in the treatment 
decision process as so little volumes were available in the medical charts. Therefore this 
probably had no major impact on the primary outcome. This registry will continue in a 
prospective fashion including more patients worldwide with a long-term follow up. A  
prospective nature will  decrease the number of missing data and the long-term  follow-up 
will support to learn more about the prognosis of PLD. 
 
Conclusion 
The results of our international cross-sectional study suggests that a higher number of 
symptoms  and every 10 years of PLD diagnosis increases the likelihood to undergo 
treatment by 40%. The choice to elect a particular modality is center dependent. The major 
implication of these findings is that physicians should bear in mind that there is no evidence 
that favors either treatment option, and this contributes to center specific preferences. 
Therefore, assessing efficacy of therapy by measuring liver volume and symptom burden, 
are essential to gain evidence among the best treatment option. Future studies comparing 
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efficacy of treatment modalities would be helpful to fill the gap of knowledge among the best 
treatment option.  
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Figure legends 
 
Figure 1. Overview of the study population. A total of 578 patients were included and 
35% (n=200) received therapy. A number of patients received ≥ 1 treatment modality. 
Figure 2. Liver cyst phenotype in ADPKD and ADPLD patients. (A) A phenotype with 
dominant cysts (≥ 8 cm) was significantly more present in ADPLD patients compared to 
ADPKD patients (22% vs. 7%, p <0.001). (B) A phenotype without dominant cysts was more 
often present in ADPKD  (93% vs. 78%, p <0.001). 
Figure 3. Forest plots showing risk ratios with 95% confidence intervals for 
respectively treatment in general, liver transplantation, fenestration and aspiration 
sclerotherapy. Risk ratios were calculated by multivariate regression analyses. A risk ratio 
of <1 represents a decreased risk and >1 increased risk for treatment. A risk ratio of 1 
(dotted line) indicates no association.  
Figure 4. Treatment strategies for PLD in autosomal dominant polycystic kidney 
disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD). Liver 
transplantation was more often done in ADPKD patients whereas fenestration and aspiration 
sclerotherapy favored ADPLD patients. 
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Tables  
 
Table 1. Characteristics of the study population 
 
                  Complete population 
                (n=578) 
Female 468 81% 
ADPKD  383 66% 
Age diagnosis PLD 45 ±13 
Center 1 380 66% 
Volumetry*  
  
TLV (mL) 4093 [2717-6066] 
hTLV (mL/m) 2639 [1669-3840] 
Phenotype* 
  
≥ 20 cysts + ≥1 dominant 
cyst 
54 11% 
≥ 20 cysts 421 89% 
Symptoms 
  
Abdominal tension 225 39% 
Feeling full 210 36% 
Abdominal pain 141 24% 
Tiredness 129 22% 
Pain rib cage 120 21% 
Pain side 78 14% 
No of symptoms 1 [1-3] 
 
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; hTLV, height adjusted total 
liver volume; PLD, polycystic liver disease; TLV, total liver volume. 
Date are in number and percentage (%), mean ±standard deviation, or median and interquartile range 
[IQR].   
Center 1= Radboud university medical center Nijmegen, the Netherlands, center 2= University 
Hospital of Leuven, Belgium 
*Data were missing in respectively 56%, 72% and 18% of patients for TLV, hTLV and phenotype 
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